Advances in the study of esophageal adenocarcinoma cell lines, model develpoment and 3D culture technology

Abstract

Abstract: Esophageal adenocarcinoma is a uncommon malignant tumor. The deterioration and metastasis of esophageal adenocarcinoma bring some difficulties and challenges to the treatment of tumor. In recent years, some progress has been made in the study of esophageal adenocarcinoma cell lines. However, there are still many unknown molecular mechanisms in tumor cells, and the differences between esophageal adenocarcinoma cells still need to be further explored. The establishment and development of esophageal adenocarcinoma cell model can be used to study the properties and characteristics of tumor cells, and various tumor cell models provide research tools for the mechanism of esophageal adenocarcinoma pathogenesis, which is conducive to understanding the abnormal expression of genes in tumor cells and the influence factors of microsignaling molecules on tumor proliferation. The 3D-culture of organoid can provide an ideal platform for the study of the heterogeneous properties and microscopic level expression of tumor cells, and provide favorable conditions for the advancement of the study of the properties of tumor cells.

Key words: esophageal adenocarcinoma, xenograft, 3D-culture, organoid

CLC Number:

R735.1

LIU Dong-jian, YANG Ling. Advances in the study of esophageal adenocarcinoma cell lines, model develpoment and 3D culture technology[J]. Basic & Clinical Medicine, 2020, 40(10): 1409-1415.

References

[1] Essakly A, Loeser H, Kraemer M, et al. Pik3ca and kras amplification in esophageal adenocarcinoma and their impact on the inflammatory tumor microenvironment and prognosis[J]. Transl Oncol, 2020, 13:157-164.
[2] Chen Y, Li LB, Zhang J, et al. Simvastatin, but not pravastatin, inhibits the proliferation of esophageal adenocarcinoma and squamous cell carcinoma cells: a cell-molecular study[J]. Lipids Health Dis, 2018, 17:290. doi: 10.1186/s12944-018-0946-7.
[3] Mari L, Hoefnagel SJM, Zito D, et al. Microrna 125a regulates mhc-i expression on esophageal adenocarcinoma cells, associated with suppression of antitumor immune response and poor outcomes of patients[J]. Gastroenterology, 2018, 155:784-798.
[4] Kong X, Gong S, Su L, et al. Expression signatures and roles of micrornas in human oesophageal adenocarcinomas[J]. J Cell Mole Med, 2018, 22:123-130.
[5] Toxopeus E, Lynam-Lennon N, Biermann K, et al. Tumor microRNA-126 controls cell viability and associates with poor survival in patients with esophageal adenocarcinoma[J]. Exp Biol Med, 2019, 244:1210-1219.
[6] Pal J, Nanjappa P, Kumar S, et al. Impact of RAD51C-mediated homologous recombination on genomic integrity in Barrett's adenocarcinoma cells[J]. J Gastroenterol Hepatol Res, 2017, 6:2286-2295.
[7] Kohtz PD, Halpern AL, Eldeiry MA, et al. Toll-like receptor-4 is a mediator of proliferation in esophageal adenocarcinoma[J]. Ann Thorac Surg, 2019, 107:233-241.
[8] Goltsov AA, Fang B, Pandita TK, et al. Her2 confers resistance to foretinib inhibition of met-amplified esophageal adenocarcinoma cells[J]. Ann Thorac Surg, 2018, 105:363-370.
[9] Hassan MS, Williams F, Awasthi N, et al. Combination effect of lapatinib with foretinib in HER2 and MET co-activated experimental esophageal adenocarcinoma[J]. Sci Rep, 2019, 9:17608. doi: 10.1038/s41598-019-54129-7.
[10] Tong Z, Mejia A, Veeranki O, et al. Targeting CDK9 and MCL-1 by a new CDK9/p-TEFb inhibitor with and without 5-fluorouracil in esophageal adenocarcinoma[J]. Ther Adv Med Oncol, 2019, 11:1758835919864850.
[11] Hong Y, Chen H, Rao Z, et al. In vitro study on the role of SOX9 in trastuzumab resistance of adenocarcinoma of the esophagogastric junction[J]. Exp Ther Med, 2018,15:3103-3107.
[12] Palethorpe HM, Drew PA, Smith E. Androgen signaling in esophageal adenocarcinoma cell lines in vitro[J]. Dig Dis Sc, 2017, 62:3402-3414.
[13] Akashi E, Fujihara S, Morishita A, et al. Effects of galectin-9 on apoptosis, cell cycle and autophagy in human esophageal adenocarcinoma cells[J]. Oncol Rep, 2017,38:506-514.
[14] Menke V, van Es JH, de Lau W, et al. Conversion of metaplastic Barrett's epithelium into post-mitotic goblet cells by gamma-secretase inhibition[J]. Dis Model Mech, 2010, 3:104-110.
[15] Schrump DS, Matthews W, Chen GA, et al. Flavopiridol mediates cell cycle arrest and apoptosis in esophageal cancer cells[J]. Clin Cancer Res, 1998, 4:2885-2890.
[16] Chen Z, Hu X, Wu Y, et al. Long non-coding RNA XIST promotes the development of esophageal cancer by sponging miR-494 to regulate CDK6 expression[J]. Biomed Pharmacother, 2019, 109:2228-2236.
[17] Du J. Upregulation of sine oculis homeobox homolog 3 is associated with proliferation, invasion, migration, as well as poor prognosis of esophageal cancer[J]. Anti Cancer Drugs, 2019, 30:596-603.
[18] Ebbing EA, Steins A, Fessler E, et al. Esophageal adenocarcinoma cells and xenograft tumors exposed to Erb-b2 receptor tyrosine Kinase 2 and 3 inhibitors activate transforming growth factor Beta signaling, which Induces epithelial to mesenchymal transition[J]. Gastroenterology, 2017, 153:63-76.
[19] Veeranki OL, Tong Z, Dokey R, et al. Targeting cyclin-dependent kinase 9 by a novel inhibitor enhances radiosensitization and identifies Axl as a novel downstream target in esophageal adenocarcinoma[J]. Oncotarget, 2019, 10:4703-4718.
[20] Buckley AM, Bibby BA, Dunne MR, et al. Characterisation of an isogenic model of cisplatin resistance in oesophageal adenocarcinoma cells[J]. Pharmaceuticals (Basel), 2019, 12.doi: 10.3390/ph12010033.
[21] Veeranki OL, Tong Z, Mejia A, et al. A novel patient-derived orthotopic xenograft model of esophageal adenocarcinoma provides a platform for translational discoveries[J]. Dis Model Mech, 2019, 12.doi: 10.1242/dmm.041004.
[22] Blum AE, Venkitachalam S, Ravillah D, et al. Systems biology analyses show hyperactivation of transforming growth factor-β and JNK signaling pathways in esophageal cancer[J]. Gastroenterology, 2019, 156:1761-1774.
[23] Teichman J, Dodbiba L, Thai H, et al. Hedgehog inhibition mediates radiation sensitivity in mouse xenograft models of human esophageal adenocarcinoma[J]. PLoS One, 2018,13:e0194809.doi: 10.1371/journal.pone.0224827.
[24] Steins A, Klaassen R, Jacobs I, et al. Rapid stromal remodeling by short-term VEGFR2 inhibition increases chemotherapy delivery in esophagogastric adenocarcinoma[J]. Mol Oncol, 2020, 14:704-720.
[25] Lin S, Liu K, Zhang Y, et al. Pharmacological targeting of p38 MAP-Kinase 6 (MAP2K6) inhibits the growth of esophageal adenocarcinoma[J]. Cell Signal, 2018, 51:222-232.